Neovasc Inc. is persevering with the international commercialization of its Reducer transcatheter device to treat angina while its path to US commercialization remains uncertain.
Neovasc Maintains Investor Confidence Despite FDA Struggles; Sells $72M In Stock
Despite a recent unfavorable FDA advisory panel for its Reducer coronary sinus device, some investors showed their faith in the Canadian company by buying 36 million shares.
